LOS ANGELES, Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that topline data from the Company's Phase 1b/2a SWARM-P.a. clinical trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) will be mentioned during the North American Cystic Fibrosis Conference (NACFC) Plenary II session. The conference is being held November 2-4, 2023, at the Phoenix Convention Center in Phoenix, AZ. Armata announced positive topline data from the SWARM-P.a. study in March 2023.
Plenary II presentation details: | ||
Title: | "Micro-Management": The Changing Face of Infections in CF | |
Presenters: | Natalie E. West, MD, MHS, Johns Hopkins University | |
Date: | Friday, November 3rd | |
Time: | 5:00pm – 6:15pm ET | |
Session: | Plenary Session II | |
Location: | North Ballroom A-D |
For more information or to register: https://www.nacfconference.org/registration
About NACFC
NACFC provides a collaborative and educational forum for all CF professionals. The educational elements of the meeting program are targeted to physicians, nurses, research scientists, respiratory therapists, physical therapists, nutritionists, social workers, and pharmacists. This annual meeting brings together scientists, clinicians, and caregivers from around the world to discuss and share ideas on the latest advances in CF research, care, and drug development and to exchange ideas about ways to improve the health and quality of life for people with CF.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
212-915-2569
| Last Trade: | US$6.06 |
| Daily Change: | -1.04 -14.65 |
| Daily Volume: | 229,092 |
| Market Cap: | US$219.550M |
October 14, 2025 September 08, 2025 August 12, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
